首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到19条相似文献,搜索用时 187 毫秒
1.
目的研究Bmi-1对MCF-7细胞阿霉素敏感性的影响及机制。方法阿霉素处理MCF-7/Bmilsi、MCF-7/GFPsi和MCF一7细胞株,M1Tr法检测阿霉素的IC50;DAPI检测阿霉素处理后细胞的凋亡,计算凋亡指数(apoptosisindex,AI);Western印迹检测相关蛋白P53,phospho—Akt(Ser473)(pAkt),totle—Akt(tAkt),Bcl-2,Bax的表达。结果阿霉素处理72h的MCF-7/Bmi.1si组生长抑制率明显高于MCF-7和MCF-7/GFPsi组,MCF-7/Bmilsi组的IC50为(0.15±0.02)μg/ml,而MCF-7组和MCF-7/GFPsi组的IC50分别为(0.87±0.06)μg/ml和(0.81±0.02)μg/ml(P〈0.05)。阿霉素处理48h后用DAPI检测凋亡发现,MCF-7/Bmi.lsi+doxorubiein组可见大量凋亡细胞,而MCF-7+doxorubicin和MCF-7/GFPsi+doxo—rubicin组出现较少的凋亡细胞,MCF-7/Bmi-1si+doxorubicin组凋亡指数明显高于对照组(P〈0.05)。进一步研究发现:MCF-7/Bmi.1si+doxorubicin组与MCF-7+doxorubiein及MCF-7/GFPsi+doxorubiein组相比,P53表达量增加,tAkt表达未发生改变,而pAkt的表达明显减少,另外,Bcl-2表达量减少而Bax表达量增加,差异具有显著性(P〈0.05)。结论沉默Bmi—l基因表达能增加MCF-7细胞对阿霉素的敏感性,增加阿霉素引起的凋亡。  相似文献   

2.
EBP50通过抑制LIMK/cofilin信号通路和PI3K/Akt/m TOR/MMP信号通路抑制乳腺癌细胞的侵袭和转移。然而,EBP50是否可以通过其他机制抑制乳腺癌细胞的侵袭和转移尚未可知。本研究发现,EBP50能通过Wnt3a/β-catenin信号通路影响乳腺癌细胞的侵袭和转移。Western印迹结果显示,EBP50在低转移细胞株MCF-7和正常乳腺细胞株MCF-10A中高表达,而在高转移细胞株MDA-MB-231低表达。采用RNAi技术将小RNA质粒瞬时转染乳腺癌细胞株MCF-7,同时将质粒pc DNA3.1-EBP50转入乳腺癌细胞株MDA-MB-231。Western印迹结果显示,Si EBP50/MCF-7细胞组的EBP50表达水平明显下调,MDA231/EBP50细胞组的EBP50表达水平明显上调。Transwell侵袭实验和划痕实验结果显示,用Wnt3a刺激后,Si EBP50/MCF-7细胞组体外迁移和侵袭能力明显增强,MDA231/EBP50细胞组体外迁移和侵袭能力明显减弱。Western印迹结果显示,与未用Wnt3a或同时用Wnt3a和抑制剂Dkk1刺激的相比,Si EBP50/MCF-7细胞组上皮-钙粘蛋白(Ecadherin)下调,波形蛋白(vimentin)上调,细胞核中β-联蛋白(β-catenin)的表达水平升高,而MDA231/EBP50细胞组上皮-钙粘蛋白上调,波形蛋白下调,细胞核中β-联蛋白表达下降。上述结果表明,EBP50通过Wnt3a/β-catenin信号通路影响β-联蛋白的转核,抑制EMT的发生,进而抑制乳腺癌细胞的侵袭和转移。  相似文献   

3.
针对来源于乳腺癌细胞MDA-MB-435的小鼠肺癌寡灶型转移肿瘤细胞株MDA-435-OL,利用慢病毒感染的方法建立稳定敲低Sec23a基因表达的细胞株MDA-435-OL-Sec23a-GFP和其阴性对照细胞株MDA-435-OL-LV3NC-GFP,通过CCK-8(Cell Counting Kit-8)增殖实验、Transwell小室细胞迁移实验、侵袭实验和琼脂克隆斑形成实验探索敲低Sec23a基因后,寡灶型转移肿瘤细胞株体外细胞生物学特性的改变。在寡灶转移细胞株中敲低Sec23a基因后,细胞生长曲线与倍增时间并没有显著差异(28.23 h和28.32 h,P0.05),但Transwell小室迁移细胞数量(58.50±2.81和39.60±3.21)、侵袭细胞数量(54.40±3.33和34.60±1.44)和细胞体外克隆形成率(0.67±0.05和0.37±0.03),均较阴性对照组显著增加(P0.001)。该研究结果表明,乳腺癌寡灶型细胞株稳定敲低Sec23a基因后,细胞的增殖特性并没有明显变化,但细胞的迁移、侵袭能力和克隆形成能力均增强。  相似文献   

4.
目的:研究BCAT1在肺癌细胞A549的增殖、迁移及侵袭能力中的作用。方法:通过小干扰RNA(si RNA)沉默A549细胞中BCAT1的表达,细胞分为对照组(Con)、BCAT1基因沉默组(si RNA-BCAT1)和si RNA阴性对照组(si RNA-NC)。利用Western blot检测si RNA对BCAT1的沉默效果;划痕愈合实验检测沉默BCAT1后A549细胞迁移能力的改变;Transwell小室侵袭实验检测沉默BCAT1后A549细胞侵袭能力的变化;MTT实验检测沉默BCAT1对A549细胞增殖能力的影响。结果:与Con组相比,si RNA-BCAT1组的BCAT1蛋白表达明显降低(P0.05),细胞划痕愈合率明显降低(P0.05),能够穿膜的细胞数明显减少(P0.05),而Con组和si RNA-BCAT1组细胞的增殖能力比较差异无明显统计学意义(P0.05)。结论:沉默BCAT1抑制A549细胞的迁移和侵袭能力,而对其增殖能力无影响。  相似文献   

5.
目的:探讨长链非编码RNA SNHG3对人乳腺癌细胞MCF-7增殖、迁移与侵袭的影响。方法:构建SNHG3过表达质粒,实验分别设置阴性对照组(pcDNA-3.1+)与SNHG3基因过表达组(pcDNA-3.1+/SNHG3)。将MCF-7细胞转染对照组质粒和SNHG3过表达质粒,采用实时定量PCR 方法检测 SNHG3 mRNA 转录水平,Western blot 检测MMP9及EMT相关蛋白质水平;集落形成实验检测MCF-7细胞增殖能力;划痕愈合实验检测MCF-7细胞横向迁移能力; Transwell 小室实验检测MCF-7细胞纵向迁移能力及侵袭能力。结果:过表达SNHG3后,MCF-7细胞中SNHG3的mRNA水平显著增高(P<0.001);MCF-7细胞的体外增殖能力明显增加(P<0.01),迁移(P<0.01)与侵袭能力(P<0.001)也显著增强,实时定量PCR, Western blot 结果显示SNHG3可激活EMT相关通路。结论:过表达SNHG3可能通过激活EMT通路促进乳腺癌MCF-7细胞的增殖,迁移与侵袭。  相似文献   

6.
目的通过TGF-β1诱导乳腺癌MCF-7发生上皮-间质转化(epithelial-mesenchymal transition,EMT)后检测锌指转录因子Snail表达的改变,探讨Snail在EMT及乳腺癌发生发展中的作用。方法常规培养乳腺癌细胞株MCF-7后,用TGF-β1诱导其发生EMT,用Transwell侵袭小室法进行细胞体外侵袭能力检测;用免疫组织化学方法及免疫荧光检测E-cadherin、Vi mentin、Snail的表达;用real ti me PCR检测E-cadherin、Vi mentin、Snail mRNA的表达。结果TGF-β1处理72h后的MCF-7细胞穿透能力明显增强。E-cadherin蛋白及mRNA表达减少,Vi mentin、Snail蛋白及mRNA表达增加。结论E-cadherin、Vi mentin是细胞发生EMT的重要生物学标志,Snail可能在转录水平上调控E-cadherin、Vi mentin蛋白的表达,Snail在EMT和乳腺癌的发生发展中起着重要的作用。  相似文献   

7.
目的:建立CRISPR/Cas9系统用于敲除人源雌激素受体α(ERα)基因(ESR1),并利用此细胞模型初步检测ESR1基因对乳腺癌细胞侵袭能力的影响。方法:设计一个靶向人源ESR1基因第2外显子的单向导RNA(sg RNA),分别克隆表达载体后,通过慢病毒转入人乳腺癌细胞株MCF-7,Western印迹检测MCF-7中ESR1基因的敲除效果,通过Transwell、反向侵袭试验观察ESR1基因敲除后对细胞侵袭能力的影响。结果:测序结果显示靶向ESR1基因CRISPR/Cas9重组质粒构建成功;Western印迹显示Cas9-ERα组的MCF-7细胞内ERα表达水平较对照组显著降低;Tanswell、反向侵袭试验证实ESR1基因敲除能够促进乳腺癌细胞的侵袭能力。结论:通过CRISPR/Cas9系统获得了靶向ESR1基因的重组质粒,构建的重组质粒能有效敲除ESR1基因;ERα能够抑制乳腺癌细胞的侵袭能力。  相似文献   

8.
目的:研究DLC-1基因对结肠癌细胞侵袭迁移能力的影响.方法:将DLC-1 shRNA(短发夹状RNA,short hairpin RNA)序列克隆到质粒pGCsi-U6/Neo载体,采用脂质体介导的转染方法将构建的DLC-1 shRNA表达质粒转入结肠癌细胞系LoVo细胞.采用RT-PCR技术和Western Blot技术分别检测LoVo细胞中DLC-1mRNA和蛋白表达水平的变化.Transwell小室人工重组基底膜侵袭转移实验观察LoVo细胞侵袭迁移能力的改变.结果:结肠癌细胞系LoVo细胞表达DLC-1分子.所构建质粒表达载体能有效地干扰LoVo细胞DLC-1 mRNA和蛋白质表达水平;Transwell小室人工重组基底膜侵袭转移实验结果显示,转染后LoVo细胞侵袭转移能力明显增强(p<0.05).结论:结肠癌细胞系LoVo细胞表达DLC-1基因,应用RNAi技术可特异性降低其表达.DLC-1的表达水平与结肠癌细胞侵袭转移相关.  相似文献   

9.
本研究旨在探究HIF-2α和Notch3在CoCl_2诱导的乳腺癌MCF-7细胞迁移和侵袭中的作用。使用CoCl_2于体外建立化学性低氧模型;采用sh RNA技术沉默MCF-7细胞中HIF-2α和Notch3基因;采用RT-PCR法检测MCF-7细胞中HIF-2α、Notch3和Hey1的m RNA水平;采用Western blot方法检测MCF-7细胞中HIF-2α、Notch3、Hey1、Snail和E-cadherin蛋白的表达水平;采用划痕实验和Transwell实验分别检测CoCl_2诱导的MCF-7细胞迁移和侵袭。结果显示,CoCl_2处理可使MCF细胞中HIF-2α、Notch3、Hey1和Snail蛋白表达水平升高(P0.05),E-cadherin蛋白表达水平下降(P0.05),促进MCF-7细胞迁移和侵袭(P0.05);沉默HIF-2α基因表达可抑制CoCl_2诱导的Notch3和Hey1的m RNA和蛋白表达(P0.05);抑制Notch3基因表达后,CoCl_2诱导的MCF-7细胞迁移和侵袭以及CoCl_2对Snail和E-cadherin蛋白表达的调节随之受到抑制(P0.05)。以上结果表明,在CoCl_2化学性低氧环境下,HIF-2α可通过强化Notch3信号通路,进而导致Snail蛋白水平升高和E-cadherin蛋白水平下降,最终提高乳腺癌MCF-7细胞的迁移和侵袭能力。  相似文献   

10.
构建真核表达载体pcDNA 3.1-Flag-T14,重组质粒经酶切分析及测序鉴定后,利用脂质体将重组质粒转染人乳腺癌细胞系MCF-7细胞,经G418筛选并建立稳定转染GALNT14细胞株.应用半定量RT-PCR、Western blot检测稳定细胞株GALNT14 mRNA及蛋白表达水平,细胞划痕修复及穿膜试验检测GALNT14基因对MCF-7迁移能力的影响,同时RT-PCR检测GALNT14对MMP-2,MMP-9,TGF-β1及VEGF等肿瘤浸润转移相关因子表达的影响.结果显示成功构建了真核重组表达载体pcDNA 3.1-Flag-T14,经RT-PCR和Western blot检测显示成功获得了稳定表达GALNT14的MCF-7细胞株;GALNT14能够提高MCF-7细胞株的迁移能力,且能增加侵袭转移相关因子MMP-2,MMP-9,TGF-β1及VEGF的表达.结论:GALNT14可明显促进MCF-7细胞的迁移,可能在肿瘤侵袭转移中起重要作用.  相似文献   

11.
The oncogene Bmi-1 is a member of the Polycomb group gene family. Its expression is found to be greatly increased in a number of malignant tumors including breast cancer. This could suggest Bmi-1 as a potent therapeutic target. In this study, RNAi was introduced to down-regulate the expression of Bmi-1 in a highly malignant breast adenocarcinoma cell line, MCF-7. A thorough study of the biological behavior and chemosensitivity changes of the MCF-7 cells was carried out in context to the therapeutic potential of Bmi-1. The results obtained indicated that siRNA targeting of Bmi-1 could lead to an efficient and specific inhibition of endogenous Bmi-1 activity. The mRNA and protein expression of Bmi-1 were determined by RT-PCR and Western blot, respectively. Furthermore, silencing of Bmi-1 resulted in a drastic inhibition of the growth of MCF-7 cells as well as G(1) /S phase transition. The number of target cells was found to increase in phase G (0) /G (1) and decrease in the S phase, but no increase in the basal level of apoptosis was noticed. On the other hand, a reduction in the expression of cyclin D1 and an increase in the expression of p21 were also noticed. Silencing of Bmi-1 made the MCF-7 cells more sensitive to the chemotherapeutic agent doxorubicin and induced a significantly higher percentage of apoptotic cells. Here, we report on a study regarding the RNAi-mediated silencing of the Bmi-1 gene in breast cancer.  相似文献   

12.
The oncogene Bmi-1 is highly up-regulated in breast carcinoma and is found to be efficient in preventing apoptosis of the cancer cells. Doxorubicin is an important chemotherapeutic agent against breast carcinoma. However, the effective therapeutic response to doxorubicin is often associated with severe toxicity. The present study is targetted at developing a strategy to increase doxorubicin sensitivity to lower doses without compromising its efficacy. A stable cell line with a persistent silencing of Bmi-1 was established. MTT assay was performed to evaluate 50% inhibitory concentration (IC50) values of doxorubicin. Apoptosis was detected by FCM and the expression of related genes [phosphor-Akt (pAkt), totle-Akt (tAkt), Bcl-2 and Bax] was studied by Western blot. In vivo, the sensitivity of the tumor tissues against doxorubicin was evaluated by transplanted MCF-7 nude mice model and the apoptosis of tissue cells was detected by TUNEL assay. The expression of pAkt and Bcl-2 was down-regulated, whereas Bax was up-regulated in Bmi-1 silencing cells. The results obtained indicated that silencing of Bmi-1 can render MCF-7 cells more sensitive to doxorubicin which induced a significantly higher percentage of apoptosis cells in vitro and in vivo. All together these results clearly demonstrate that Bmi-1 siliencing combined treatment of doxorubicin might be a new strategy for biological treatment on breast cancer.  相似文献   

13.
目的:通过敲低微小RNA (microRNA,miRNA)-449a的方法研究miR-449a对人乳腺癌细胞MCF-7的增殖和迁移能力的影响。方法:采用miRNA芯片在乳腺癌细胞MCF-7和人正常乳腺细胞MCF-10A筛选具有表达差异的miRNA;化学合成法制备miR-449a的抑制剂(inhibitor),转染后经real-time PCR验证表达的变化;细胞增殖CCK-8实验对转染后细胞增殖能力进行检测;划痕实验检测细胞转移能力,transwell小室实验检测细胞侵袭的改变;蛋白免疫印迹法(Western blot)实验对MCF-7细胞增殖和迁移相关的β-catenin和E-cadherin蛋白进行检测;通过生物信息学软件预测miR-449a潜在靶基因为Notch 1,荧光素酶实验检测Notch 1是miR-449a的靶基因。结果:分别收集MCF-7和MCF-10A细胞,芯片结果显示miR-449a在MCF-7细胞的表达水平显著高于MCF-10A;本研究将细胞分为未处理组(Mock组),阴性对照组(negative control组,NC组)和处理组,通过收集不同组MCF-7细胞进行试验,CCK-8结果显示miR-449a下调后MCF-7细胞增殖能力显著降低;划痕实验结果显示miR-449a表达降低导致MCF-7细胞转移能力降低;transwell实验结果显示MCF-7细胞侵袭受到抑制;Western blot结果发现miR-449a敲低后β-catenin表达降低,E-cadherin表达增加;荧光素酶试验结果显示,miR-449a能够显著降低Notch 1-3'-UTR质粒的荧光素活性(P<0.01)。结论:在乳腺癌细胞MCF-7中敲低miR-449a能够显著抑制癌细胞增殖和迁移,而这一变化可能通过降低Notch 1蛋白表达实现的。  相似文献   

14.
15.
16.
目的: 构建重组慢病毒介导的NUP88-shRNA载体,通过RNAi技术分别观察沉默NUP88后对MCF-7增殖,粘附,侵袭和转移情况的影响,为乳腺癌的临床基因治疗寻找新的靶点。方法: 构建NUP88重组慢病毒表达载体,包装后检测滴度,以最佳复感染指数转染乳腺癌MCF-7细胞,利用RT-PCR和Western blot检测各组MCF-7细胞中mRNA和蛋白的表达效率;MTT法和流式细胞仪检测法,检测NUP88基因被干扰后对MCF-7细胞增殖和凋亡的影响;细胞侵袭实验检测NUP88基因被干扰后对MCF-7侵袭力的影响。结果 四组病毒及一组阴性对照均构建成功,滴度均为4E+8TU/ml;RT-PCR和Western blot检测,结果表明:经NUP88-shRNA转染的MCF-7细胞组NUP88 mRNA和蛋白质的表达与经阴性转染组和空白MCF-7细胞组相比,差异明显具有统计学意义(P<0.01);测定NUP88-shRNA1组沉默效率最高,沉默率可达到86%;MTT法结果表明:实验组经NUP88-shRNA1慢病毒转染后细胞增殖程度显著减少,与空白组和对照组相比有显著性差异(P<0.05)。流式细胞仪检测三组MCF-7细胞凋亡结果表明:实验组经慢病毒转染后细胞凋亡率显著增加,与对照组和空白组相比有显著性差异(P<0.05);细胞侵袭实验表明:在肿瘤细胞常规培养24h后,实验组与空白组和阴性对照组比较,穿膜细胞数量明显减少,具有显著性差异(P<0.05) 结论: NUP88重组慢病毒可以通过RNAi成功抑制MCF-7中NUP88基因的表达,并能显著抑制其增殖及远处的侵袭能力。  相似文献   

17.
Breast cancer is the most frequent malignancy in women and drug resistance is the major obstacle for its successful chemotherapy. In the present study, we analyzed the involvement of an oncofetal gene, sal-like 4 (SALL4), in the tumor proliferation and drug resistance of human breast cancer. Our study showed that SALL4 was up-regulated in the drug resistant breast cancer cell line, MCF-7/ADR, compared to the other five cell lines. We established the lentiviral system expressing short hairpin RNA to knockdown SALL4 in MCF-7/ADR cells. Down-regulation of SALL4 inhibited the proliferation of MCF-7/ADR cells and induced the G1 phase arrest in cell cycle, accompanied by an obvious reduction of the expression of cyclinD1 and CDK4. Besides, down-regulating SALL4 can re-sensitize MCF-7/ADR to doxorubicin hydrochloride (ADMh) and had potent synergy with ADMh in MCF-7/ADR cells. Depletion of SALL4 led to a decrease in IC50 for ADMh and an inhibitory effect on the ability to form colonies in MCF-7/ADR cells. With SALL4 knockdown, ADMh accumulation rate of MCF-7/ADR cells was increased, while the expression of BCRP and c-myc was significantly decreased. Furthermore, silencing SALL4 also suppressed the growth of the xenograft tumors and reversed their resistance to ADMh in vivo. SALL4 knockdown inhibits the growth of the drug resistant breast cancer due to cell cycle arrest and reverses tumor chemo-resistance through down-regulating the membrane transporter, BCPR. Thus, SALL4 has potential as a novel target for the treatment of breast cancer.  相似文献   

18.
为探讨CXCL1基因对三阴性乳腺癌细胞MDA-MB-231的迁移、侵袭作用的影响,该研究设计针对CXCL1基因的小干扰RNA,用实时荧光定量PCR和酶联免疫吸附测定试验分别在RNA和蛋白质水平上检测干扰效率;采用流式细胞术学技术检测细胞的周期和凋亡情况;采用transwell迁移和侵袭试验分别检测细胞的迁移及侵袭能力。结果显示,与siRNA-NC组细胞相比,siCXCL1-1、siCXCL1-2、siCXCL1-3细胞中CXCL1基因的mRNA和蛋白表达均下调,且si CXCL1-3干扰效率最高,mRNA及蛋白表达水平分别降低了75%(p<0.01)和46%(p<0.01)。细胞凋亡试验和细胞周期试验结果显示,沉默CXCL1基因后对三阴性乳腺癌细胞系MDA-MB-231细胞的凋亡和周期无明显影响,差异无统计学意义(p>0.05)。transwell小室迁移和侵袭试验显示,沉默CXCL1基因能够显著抑制三阴性乳腺癌细胞MDA-MB-231的迁移和侵袭能力(p<0.01)。研究成果为临床乳腺癌中以CXCL1基因为靶点的分子治疗提供了理论依据。  相似文献   

19.
目的:探讨有丝分裂检查点蛋白着丝粒蛋白-E(CENP-E)基因在肿瘤发生发展中的作用。方法:利用shRNA下调CENP-E基因的表达,分别用巢式PCR和Western blot检测CENP-E mRNA和蛋白的表达;MTT检测CENP-E下调后MCF-7细胞的增殖变化;流式细胞术检测CENP-E下调后对MCF-7细胞凋亡的影响;Transwell试验检测MCF-7细胞的迁移和侵袭能力变化;间接免疫荧光检测细胞内CENP-E蛋白和有丝分裂情况。结果:shRNA能有效抑制CENP-E mRNA和蛋白的表达。MTT结果显示CENP-E下调后MCF-7细胞的增殖能力减弱(P<0.05);流式细胞术显示下调CENP-E后能促进MCF-7细胞的凋亡;间接荧光结果显示CENP-E干扰后MCF-7细胞内CENP-E蛋白减少并伴有核分裂异常;Transwell试验显示CENP-E干扰组细胞的迁移和侵袭能力增强(P<0.05)。结论:下调部分CENP-E的表达能抑制MCF-7细胞的增殖,促进MCF-7细胞的凋亡,增强MCF-7细胞的迁移和侵袭能力。  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号